ETF Holdings Breakdown of PTGX

Stock NameProtagonist Therapeutics Inc
TickerPTGX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS74366E1029

News associated with PTGX

Marshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company’s stock after selling 295,657 shares during the quarter. […] - 2025-05-02 08:30:50
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Mariner LLC
Mariner LLC increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,983 shares of the company’s stock after buying an additional 2,004 shares during the period. Mariner LLC’s holdings in Protagonist Therapeutics were worth […] - 2025-04-30 08:19:01
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44
Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation […] - 2025-04-28 05:22:54
Barclays PLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Barclays PLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 126,733 shares of the company’s stock after selling 262 shares during the period. Barclays PLC’s holdings in Protagonist Therapeutics were worth $4,891,000 as of its most recent SEC filing. A […] - 2025-04-27 08:24:54
Bank of Montreal Can Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Bank of Montreal Can grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,250 shares of the company’s stock after acquiring an additional 270 shares during the quarter. Bank of Montreal Can’s holdings in Protagonist Therapeutics were worth $241,000 […] - 2025-04-25 07:36:55
Geode Capital Management LLC Acquires 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Geode Capital Management LLC raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,377,063 shares of the company’s stock after purchasing an additional 2,366 shares during the quarter. […] - 2025-04-14 08:00:52
Wellington Management Group LLP Acquires 909,998 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Wellington Management Group LLP boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3,025.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 940,077 shares of the company’s stock after purchasing an additional 909,998 shares during the period. Wellington Management […] - 2025-04-07 08:27:05
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Decreased by Prudential Financial Inc.
Prudential Financial Inc. cut its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 1.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,998 shares of the company’s stock after selling 800 shares during the quarter. Prudential Financial Inc. owned […] - 2025-04-04 07:37:01
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $62.56 Consensus Target Price from Brokerages
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to […] - 2025-04-03 05:22:47
Cibc World Markets Corp Acquires New Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Cibc World Markets Corp bought a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,468 shares of the company’s stock, valued at approximately $211,000. Other large investors have also recently added to or […] - 2025-03-27 08:54:56
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Victory Capital Management Inc.
Victory Capital Management Inc. raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 84.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 240,817 shares of the company’s stock after buying an additional 110,020 shares during the period. Victory Capital Management Inc.’s holdings in Protagonist Therapeutics were worth $9,296,000 […] - 2025-03-14 07:50:48
BMO Capital Markets Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital Markets from $62.00 to $72.00 in a report released on Tuesday, Marketbeat reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 24.89% from the stock’s […] - 2025-03-13 07:50:56
Bank of New York Mellon Corp Grows Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Bank of New York Mellon Corp boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 390,788 shares of the company’s stock after buying an additional 34,455 shares during the quarter. Bank […] - 2025-03-13 07:11:00
PTGX Crosses Above Average Analyst Target
In recent trading, shares of Protagonist Therapeutics Inc (Symbol: PTGX) have crossed above the average analyst 12-month target price of $59.30, changing hands for $59.76/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-03-12 10:52:21
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 at Truist Financial
Protagonist Therapeutics (NASDAQ:PTGX – Free Report) had its price objective hoisted by Truist Financial from $60.00 to $76.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock. Other equities analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and […] - 2025-03-12 08:42:49
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Buy” from Brokerages
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating […] - 2025-03-11 05:58:52
Contrasting Protagonist Therapeutics (NASDAQ:PTGX) and Amicus Therapeutics (NASDAQ:FOLD)
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability. Risk & Volatility Protagonist Therapeutics has a […] - 2025-03-10 06:24:53
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by New York State Common Retirement Fund
New York State Common Retirement Fund cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 11.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 17,882 shares of the company’s stock after selling 2,300 shares during the period. New York State Common […] - 2025-03-04 08:34:48
Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 target price on the stock. Several other equities research analysts also recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued […] - 2025-03-04 06:53:05
The Goldman Sachs Group Cuts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $38.00
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price objective cut by research analysts at The Goldman Sachs Group from $43.00 to $38.00 in a report released on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 8.29% from […] - 2025-02-26 08:24:50
Bleakley Financial Group LLC Sells 664 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Bleakley Financial Group LLC cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,367 shares of the company’s stock after selling 664 shares during the period. Bleakley […] - 2025-02-12 09:34:49
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $56.00 Consensus Price Target from Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-02-12 06:10:45
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by KBC Group NV
KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,093 shares of the company’s stock after buying an additional 737 shares during the quarter. […] - 2025-02-10 18:30:59
JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX)
JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $58.00 price target on the stock. PTGX has been the topic of a number of other reports. JPMorgan Chase & Co. increased their price objective on […] - 2025-02-10 17:04:47

PTGX institutional holdings

The following institutional investment holdings of PTGX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-09 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 35,165USD 1,511,040
2025-05-09 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 19,921USD 856,005
2025-05-09 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 29,231USD 1,256,056
2025-05-09 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 29,231USD 1,256,056 -2.2%
2025-05-09 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 361USD 15,512
Total =113,909 USD 4,894,669
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.